Novacyt H1 Loss Narrows, Revenue Rises 18%

Novacyt’s September liquidity-agreement trading saw Invest Securities buy 44,200 shares and sell 44,422; the company reported 65,577 shares held in treasury and 72,588,088 ordinary shares outstanding for voting-interest calculations. For the first half of 2026, revenue rose 18% to £11.56 million and net loss narrowed to £5.79 million from £6.34 million a year earlier, with the company citing lower expenses and cost-saving measures. Novacyt also reported a cash runway to September 2027, launched an IVDR-certified DPYD assay, began work under a five-year Illumina collaboration and said its Southern Cross Diagnostics acquisition contributed £1.8 million in revenue during its first four months.